Biotech Values

[io_io]

Seattle Times:

That's a fantastic ground-breaking piece of journalism.

I thought biotech was the one place where research (in my case, aided by BTM and iHub), logic and patience would help one get ahead. But the playing-field here is not level either, not even close.

Now I'm thinking: no wonder DNDN never really moved since the early peek at 9902a. Of course it was a lot worse for those holding other stocks, such as mentioned in the article.